Annals of Operations Research

, Volume 226, Issue 1, pp 589–621

A hybrid fuzzy MCDM method for measuring the performance of publicly held pharmaceutical companies

  • Madjid Tavana
  • Kaveh Khalili-Damghani
  • Rahman Rahmatian
Article

DOI: 10.1007/s10479-014-1738-8

Cite this article as:
Tavana, M., Khalili-Damghani, K. & Rahmatian, R. Ann Oper Res (2015) 226: 589. doi:10.1007/s10479-014-1738-8

Abstract

Maximizing shareholders’ value has always been an indispensable goal for publicly traded companies. Shareholders value is highly dependent on the operating expenses, profit margin, return on investment and the overall performance in public companies. We propose a hybrid fuzzy multi-criteria decision making method for measuring the performance of publicly held companies in the Pharmaceutical industry. The proposed method helps investors choose a proper portfolio of stocks in the presence of environmental turbulence and uncertainties. The proposed method is composed of three distinct but inter-related phases. In the pre-screening phase, a set of financial and non-financial evaluation criteria are selected based on the balanced scorecard (BSC) approach. In the efficiency measurement phase, the DEMATEL method is used first to determine the inter-relationships among the BSC perspectives. A fuzzy ANP method is used next to determine the relative importance of the criteria based on the resulting DEMATEL interactive network. In the third step, two different fuzzy data envelopment analysis (DEA) methods are used to evaluate the relative efficiency of the decision making units (DMUs). The fuzzy DEA models are modified by using the relative importance of the criteria and the precedence relations among the input and output weights as additional constraints. Finally, the modified fuzzy DEA models are used to calculate the relative efficiency scores of the DMUs. In the ranking phase, an integration method grounded in the Shannon’s entropy concept is used to combine different efficiency scores and calculate the final ranking of the DMUs. The method proposed in this study is used to evaluate the performance of publicly held pharmaceutical companies actively trading on the Swiss Stock Exchange (SSE).

Keywords

Performance evaluation Balanced scorecard DEMATEL Fuzzy ANP Fuzzy DEA 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Madjid Tavana
    • 1
    • 2
  • Kaveh Khalili-Damghani
    • 3
  • Rahman Rahmatian
    • 4
  1. 1.Lindback Distinguished Chair of Information Systems and Decision Sciences, Business Systems and Analytics DepartmentLa Salle UniversityPhiladelphiaUSA
  2. 2.Business Information Systems Department, Faculty of Business Administration and EconomicsUniversity of PaderbornPaderbornGermany
  3. 3.Department of Industrial Engineering, South-Tehran BranchIslamic Azad UniversityTehranIran
  4. 4.Department of Industrial Engineering, Science and Research BranchIslamic Azad UniversitySavehIran

Personalised recommendations